Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone-marrow-transplant recipients

R. Saral, W. H. Burns, O. L. Laskin, G. W. Santos, P. S. Lietman

Research output: Contribution to journalArticle

Abstract

We conducted a double-blind, placebo-controlled study of acyclovir prophylaxis against infection with herpes simplex virus (HSV) in 20 seropositive recipients of bone-marrow transplants. Acyclovir or placebo was administered for 18 days, starting three days before transplantation. Culture-positive HSV lesions developed during the study in seven of the 10 patients who received placebo. In contrast, no such lesions appeared in the 10 patients who received acyclovir (P~0.003). None of the patients had evidence of drug toxicity. Five of the patients treated with acyclovir had mild culture-positive HSV infections after cessation of the drug, and two additional patients shed virus without having lesions. Acyclovir appears to be a potent inhibitor of HSV replication. Although acyclovir does not appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalNew England Journal of Medicine
Volume305
Issue number2
StatePublished - 1981
Externally publishedYes

Fingerprint

Acyclovir
Virus Diseases
Simplexvirus
Bone Marrow
Placebos
Infection
Virus Replication
Drug-Related Side Effects and Adverse Reactions
Transplant Recipients
Transplantation
Viruses
Transplants
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone-marrow-transplant recipients. / Saral, R.; Burns, W. H.; Laskin, O. L.; Santos, G. W.; Lietman, P. S.

In: New England Journal of Medicine, Vol. 305, No. 2, 1981, p. 63-67.

Research output: Contribution to journalArticle

Saral, R. ; Burns, W. H. ; Laskin, O. L. ; Santos, G. W. ; Lietman, P. S. / Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone-marrow-transplant recipients. In: New England Journal of Medicine. 1981 ; Vol. 305, No. 2. pp. 63-67.
@article{fc197c5befdb40ccb55272d4cdec95ae,
title = "Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone-marrow-transplant recipients",
abstract = "We conducted a double-blind, placebo-controlled study of acyclovir prophylaxis against infection with herpes simplex virus (HSV) in 20 seropositive recipients of bone-marrow transplants. Acyclovir or placebo was administered for 18 days, starting three days before transplantation. Culture-positive HSV lesions developed during the study in seven of the 10 patients who received placebo. In contrast, no such lesions appeared in the 10 patients who received acyclovir (P~0.003). None of the patients had evidence of drug toxicity. Five of the patients treated with acyclovir had mild culture-positive HSV infections after cessation of the drug, and two additional patients shed virus without having lesions. Acyclovir appears to be a potent inhibitor of HSV replication. Although acyclovir does not appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections.",
author = "R. Saral and Burns, {W. H.} and Laskin, {O. L.} and Santos, {G. W.} and Lietman, {P. S.}",
year = "1981",
language = "English (US)",
volume = "305",
pages = "63--67",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "2",

}

TY - JOUR

T1 - Acyclovir prophylaxis of herpes-simplex-virus infections. A randomized, double-blind, controlled trial in bone-marrow-transplant recipients

AU - Saral, R.

AU - Burns, W. H.

AU - Laskin, O. L.

AU - Santos, G. W.

AU - Lietman, P. S.

PY - 1981

Y1 - 1981

N2 - We conducted a double-blind, placebo-controlled study of acyclovir prophylaxis against infection with herpes simplex virus (HSV) in 20 seropositive recipients of bone-marrow transplants. Acyclovir or placebo was administered for 18 days, starting three days before transplantation. Culture-positive HSV lesions developed during the study in seven of the 10 patients who received placebo. In contrast, no such lesions appeared in the 10 patients who received acyclovir (P~0.003). None of the patients had evidence of drug toxicity. Five of the patients treated with acyclovir had mild culture-positive HSV infections after cessation of the drug, and two additional patients shed virus without having lesions. Acyclovir appears to be a potent inhibitor of HSV replication. Although acyclovir does not appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections.

AB - We conducted a double-blind, placebo-controlled study of acyclovir prophylaxis against infection with herpes simplex virus (HSV) in 20 seropositive recipients of bone-marrow transplants. Acyclovir or placebo was administered for 18 days, starting three days before transplantation. Culture-positive HSV lesions developed during the study in seven of the 10 patients who received placebo. In contrast, no such lesions appeared in the 10 patients who received acyclovir (P~0.003). None of the patients had evidence of drug toxicity. Five of the patients treated with acyclovir had mild culture-positive HSV infections after cessation of the drug, and two additional patients shed virus without having lesions. Acyclovir appears to be a potent inhibitor of HSV replication. Although acyclovir does not appear to eradicate latent infection, it can provide effective prophylaxis against reactivated infections.

UR - http://www.scopus.com/inward/record.url?scp=0019842283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019842283&partnerID=8YFLogxK

M3 - Article

C2 - 6264292

AN - SCOPUS:0019842283

VL - 305

SP - 63

EP - 67

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 2

ER -